ADVANCED THERAPIES COMMITTEE CHAIR PREDICTS SURGE IN HIGH LEVEL MEDICINE DEVELOPMENT
February 1st, 2013 THE EUROPEAN Medicines Agency’s committee for advanced therapies has predicted a surge in market approval applications (MAAs) for such specialist medicines. Committee chair Christian Schneider said: “With the approval of the first gene therapy in 2012, the CAT is paving the way for the approval of similarly complex medicines…as more gene therapies for rare diseases, personalised medicines and nanomedicines are on their way.” EMA last year approved a treatment for lipoprotein lipase (LPL) deficiency. And a note from the committee said: “While the number ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.